ClinicalTrials.gg

Program

Caffeine

Also written as “caffeine”, “ibuprofen + caffeine” and “Paracetamol and Caffeine”.

Its studies are mostly in Pain · Neoplasms · Pain, Postoperative · Common Cold · Obesity, led by 6 companies.

Furthest: phase 4, since Aug 22, 201316 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim60 open or runningphase 3since Aug 22, 2013Jun 13, 2013none ahead
GlaxoSmithKline50 open or runningphase 4since Nov 3, 2011Mar 1, 2007none ahead
Pfizer20 open or runningphase 3since Aug 8, 2016Aug 8, 2016none ahead
Hypera Pharma10 open or runningphase 3since Jul 28, 2010Jul 28, 2010none ahead
Novartis10 open or runningphase 4since Nov 23, 2010Nov 23, 2010none ahead
Sanofi10 open or runningphase 3since Aug 31, 2011Aug 31, 2011none ahead

Also a collaborator on its studies: medpace-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Mar 1, 2007.

  1. Nov 23, 2010Novartis's first study: phase 4 study in PainNew to NovartisNovartis · NCT01248468 · 752 enrolled · United States
  2. Aug 31, 2011Sanofi's first study: phase 3 study in PainNew to SanofiSanofi · NCT01426971
  3. Nov 3, 2011Phase 4 study in Common ColdGlaxoSmithKline · NCT01466348 · 72 enrolled · United Kingdom
  4. Sep 13, 2012Phase 3 study in Common ColdGlaxoSmithKline · NCT01686646 · 240 enrolled · United Kingdom
  5. Apr 25, 2013Phase 3 study in PainGlaxoSmithKline · NCT01842633 · 365 enrolled · United States
  6. Jun 13, 2013Boehringer Ingelheim's first study: phase 1 study in HealthyNew to Boehringer IngelheimBoehringer Ingelheim · NCT01879371 · 36 enrolled · Germany
  7. Aug 22, 2013Phase 3 study in Pain, PostoperativeBoehringer Ingelheim · NCT01929031 · 562 enrolled · United States
  8. Jul 7, 2014Phase 3 study in Migraine DisordersBoehringer Ingelheim · NCT02183688 · 1,889 enrolled
  9. Dec 10, 2015Phase 1 study in HealthyBoehringer Ingelheim · NCT02629354 · 36 enrolled · South Africa
  10. Aug 8, 2016Pfizer's first study: phase 3 study in PainNew to PfizerPfizer · NCT02863575 · 374 enrolled · United States
  11. Sep 19, 2016Phase 4 study in PainGlaxoSmithKline · NCT02974114 · 21 enrolled · United Kingdom
  12. Nov 17, 2016Phase 3 study in Back PainBoehringer Ingelheim · NCT03003000 · 635 enrolled · Germany, Russian Federation
  13. Dec 3, 2020Phase 1 study in Healthy ParticipantsPfizer · NCT04655040 · 12 enrolled · United States
  14. Feb 14, 2023No phase study in Liver CirrhosisBoehringer Ingelheim · NCT05741385 · 4 enrolled · Germany

TargetBeta

“Adenosine receptor antagonist; Adenosine receptor antagonist”ChEMBL 37, by rule

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05741385Liver Cirrhosis · Germany–CompletedBoehringer IngelheimAug 9, 20244
NCT04655040Healthy Participants · United States1CompletedPfizerMar 5, 202112
NCT03003000Back Pain · Germany, Russian Federation3CompletedBoehringer IngelheimSep 24, 2017635
NCT02974114Pain · United Kingdom4TerminatedGlaxoSmithKlineFeb 6, 201721
NCT02863575Pain · United States3CompletedPfizerApr 6, 2018374
NCT02629354Healthy · South Africa1CompletedBoehringer IngelheimJan 201636
NCT02183688Migraine Disorders3CompletedBoehringer IngelheimJan 20031,889
NCT01929031Pain, Postoperative · United States3CompletedBoehringer IngelheimMar 2014562
NCT01879371Healthy · Germany1CompletedBoehringer IngelheimJul 201336
NCT01842633Pain · United States3TerminatedGlaxoSmithKlineMar 31, 2015365
NCT01686646Common Cold · United Kingdom3CompletedGlaxoSmithKlineNov 2012240
NCT01466348Common Cold · United Kingdom4CompletedGlaxoSmithKlineApr 201172
NCT01426971Pain3WithdrawnSanofiJun 20130
NCT01248468Pain · United States4CompletedNovartisMar 2011752
NCT01172405Headache3UNKNOWNHypera PharmaOct 2012144
NCT00443170Anemia · Australia1CompletedGlaxoSmithKline90

How it is read

Names in the registry

  • “Caffeine”, 11 entries
  • “caffeine”, 4 entries
  • “ibuprofen + caffeine”, 3 entries
  • “Paracetamol and Caffeine”, 2 entries
  • “Cocktail (Warfarin/Caffeine/Midazolam)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.